- Home
- BWAY vs SCPH Comparison
BWAY vs SCPH Comparison
Compare BWAY & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- SCPH
- Stock Information
- Founded
- BWAY 2003
- SCPH 2013
- Country
- BWAY Israel
- SCPH United States
- Employees
- BWAY N/A
- SCPH N/A
- Industry
- BWAY Medical/Dental Instruments
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- BWAY Health Care
- SCPH Health Care
- Exchange
- BWAY Nasdaq
- SCPH Nasdaq
- Market Cap
- BWAY 207.4M
- SCPH 173.6M
- IPO Year
- BWAY 2019
- SCPH 2017
- Fundamental
- Price
- BWAY $8.24
- SCPH $2.57
- Analyst Decision
- BWAY Strong Buy
- SCPH Strong Buy
- Analyst Count
- BWAY 3
- SCPH 3
- Target Price
- BWAY $13.17
- SCPH $14.00
- AVG Volume (30 Days)
- BWAY 31.1K
- SCPH 519.0K
- Earning Date
- BWAY 05-07-2025
- SCPH 05-13-2025
- Dividend Yield
- BWAY N/A
- SCPH N/A
- EPS Growth
- BWAY N/A
- SCPH N/A
- EPS
- BWAY 0.09
- SCPH N/A
- Revenue
- BWAY $41,016,000.00
- SCPH $36,332,000.00
- Revenue This Year
- BWAY $349.63
- SCPH $114.00
- Revenue Next Year
- BWAY $27.16
- SCPH $77.45
- P/E Ratio
- BWAY $54.30
- SCPH N/A
- Revenue Growth
- BWAY 29.04
- SCPH 167.28
- 52 Week Low
- BWAY $4.61
- SCPH $1.94
- 52 Week High
- BWAY $11.79
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- BWAY 32.71
- SCPH 47.35
- Support Level
- BWAY $8.29
- SCPH $1.94
- Resistance Level
- BWAY $8.58
- SCPH $2.71
- Average True Range (ATR)
- BWAY 0.53
- SCPH 0.27
- MACD
- BWAY -0.05
- SCPH 0.04
- Stochastic Oscillator
- BWAY 14.81
- SCPH 76.36
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.